All In Biotech

Investigational drug · Phase 2

FWY003

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Geographic Atrophy Secondary to Age-related Macular Degeneration.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "FWY003"

First trial start

2026

Mar 9, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "FWY003", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "FWY003" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Geographic Atrophy Secondary to Age-related Macular Degeneration

  • siRNAADX-038, ADX-324Phase 37 trials

    ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1

  • APL-3007Phase 21 trial

    Apellis Pharmaceuticals, Inc. · Geographic Atrophy Secondary to Age-related Macular Degeneration

  • RO7965032Phase 21 trial

    Roche (Genentech) · Geographic Atrophy Secondary to Age-Related Macular Degeneration

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.